cancer type cervical cancer
LncRNA EBIC is up-regulated in cervical cancer (CC). EBIC silencing impairs CC cells migration and invasion. Moreover, EBIC can bind to EZH2. Furthermore, EBIC could inhibit E-cadherin by associating with EZH2, therefore EBIC might act as a facilitator in recruiting EZH2 to the promoter region of E-cadherin. EBIC and EZH2 may be two interdependent components of the H3K27me3 process
cancer type hepatic cancer
LncRNA EGFR-AS1 is up-regulated in hepatocellular carcinoma tissues and correlated with portal vein thrombosis, lymph metastasis and poor prognosis. EGFR-AS1 knockdown can decrease the expression of EGFR in vitro. In addition, growth hormone receptor (GHR) can promote the expression of EGFR and EGFR-AS1. Inhibition of EGFR-AS1 impedes cell proliferation, cell migration and EMT. EGFR-AS1 can also reduce E-cadherin and increase N-cadherin.
cancer type breast cancer
LncRNA EGOT expression is lower in breast cancer compared with the adjacent noncancerous tissues, and low levels of EGOT expression are significantly correlated with larger tumor size, more lymph node metastasis and higher Ki-67 expression. Moreover, patients with low levels of EGOT expression show significantly worse prognosis for overall survival.
cancer type breast cancer
LncRNA ENST00000515084 expression is predominantly cytoplasmic. The C allele of the rs12325489C>T polymorphism in the exonic regions of ENST00000515084 is associated with a significantly increased risk of breast cancer, compared with the rs12325489TT genotype. Biochemical analysis demonstrates that the C to T base change at rs12325489C>T disrupts the binding site for miRNA-370, thereby influencing the transcriptional activity of ENST00000515084 in vitro and in vivo, further affecting cell proliferation and tumor growth.
cancer type papillary thyroid cancer
LncRNA ENST00000537266 is up-regulated in papillary thyroid carcinoma (PTC). It can promote PTC cell proliferation and motility.
cancer type breast cancer,lung cancer,renal cancer
LncRNA EPB41L4A-AS2 is down-regulated in breast, renal and lung cancer. Low expression is correlated with larger tumor size, higher stage and grade, ER and PR negative expression. Besides, low expression is correlated with poorer survival of the three kinds of cancers. In addition, a better overall survival is observed in TP53 wild-type breast cancer patients with high EPB41L4A-AS2 expression, while the converse is found for breast cancer patients with a TP53 mutation. Furthermore, overexpression of EPB41L4A-AS2 inhibits tumor cell proliferation.
cancer type non-small-cell lung cancer
LncRNA ERICH1-AS1 is significantly up-regulated in non-small cell lung cancer samples and can be used as diagnostic marker.
cancer type Ewing sarcoma
LncRNA EWSAT1 is up-regulated by EWS-FLI1 in primary pediatric human mesenchymal progenitor cells (pMPCs). Inhibition of EWSAT1 expression diminishes the ability of Ewing sarcoma cell lines to proliferate, whereas EWSAT1 inhibition has no effect on other cell types tested. In addition, heterogeneous nuclear ribonucleoprotein (HNRNPK) is an RNA-binding protein that interacts with EWSAT1 and overlap in HNRNPK-repressed genes and those repressed by EWS-FLI1 and EWSAT1.
cancer type esophageal squamous cell cancer
LncRNA Epist is down-regulated in esophageal squamous cell carcinoma (ESCC). Epist can inhibit migration and invasion, which indicates Epist functions as a tumor suppressing lncRNA in ESCC.